K-PHOS #2 Rx
Generic Name and Formulations:
Potassium acid phosphate 305mg, sodium acid phosphate 700mg; equiv. to potassium 2.3mEq and sodium 5.8mEq; tabs.
Indications for K-PHOS #2:
1 tab 4 times a day with a full glass of water. If urine very alkaline, 1 tab every 2 hours; max 8 tabs daily.
Renal or adrenal insufficiency. Severe hepatic disease. Infected phosphate stones. Hyperphosphatemia. Hyperkalemia (Original).
Electrolyte restrictions. Cardiac disease. Hypertension. Edema. Monitor serum electrolytes and for GI obstruction. Discontinue if laxation persists after dosage reduction. Hypoparathyroidism. Osteomalacia. Pancreatitis. Dehydration. Toxemia of pregnancy. Pregnancy (Cat.C). Nursing mothers.
Antagonized by antacids. Hyperkalemia with ACE inhibitors, triamterene, spironolactone, amiloride, potassium supplements. Toxicity with digitalis. Hypernatremia with methyldopa, guanethidine, other antihypertensives, corticotropins, mineralocorticoids.
Small bowel lesions, laxation, headache, dizziness, hyperacidity, nausea, weakness, confusion, paresthesias, seizures, arrhythmias, shortness of breath, edema.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds